Natera attracted Evercore ISI’s Outperform rating and a $170 price target on recognition of its leading position in the minimal residual disease (MRD) detection market through its Signatera test. The company commands approximately an 80% share in a market still under 5% penetration. Recently, Signatera secured broad Medicare coverage for several oncology indications, supporting expectations for over 30% growth through 2027. While competition and pricing pressure are potential risks, Natera’s sustained leadership is underpinned by ongoing clinical trials, guideline inclusions, and product pipeline advancements in oncology and women's health.